Health Care & Life Sciences » Pharmaceuticals » Orphan drugs | Top orphan drug revenues by drug 2017

Top global orphan drugs by revenue 2017

Top global orphan drugs by revenue in 2017 (Figures expressed in billions of U.S. dollars, unless otherwise specified)

The data displays the top pharmaceutical orphan drugs worldwide based on the revenues in 2017. During that year, Revlimid marketed by Celgene was the world's top orphan drug, generating over eight billion USD in revenue. Orphan drugs are developed to treat a specific rare medical condition, often called an orphan disease. In many countries, public policy determines the characteristics behind specifying orphan diseases and drugs.

Revlimid (Celgene/BelGene) 8.2
Rituxan (Roche) 7.5
Opdivo (BMS/Ono) 5.7
Keytruda (Merck & Co/Otsuka) 3.8
Imbruvica (AbbVie/J&J) 3.2
Soliris (Alexion) 3.1
Jakafi (Incyte/Novartis 1.9
Pomalyst (Celgene) 1.6
Darzalex (J&J) 1.2